# A Study of Imlunestrant (LY3484356) in Female Healthy Participants

> **NCT05444556** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 113 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Imlunestrant
- **DRUG:** Repaglinide
- **DRUG:** Omeprazole
- **DRUG:** Dextromethorphan
- **DRUG:** Quinidine
- **DRUG:** Rosuvastatin
- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT05444556
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2022-11-02
- **Final completion:** 2022-11-02
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05444556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05444556, "A Study of Imlunestrant (LY3484356) in Female Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05444556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*